NIH-funded research R01 grant

Understanding how prostate cancer changes from one type to another

Official title: Molecular Mechanisms Underlying Luminal- Neuroendocrine Transdifferentiation

Funded at Emory University · NIH-10982139 · Data updated 2026-11-12

This study is looking at how prostate cancer changes into a tougher form called neuroendocrine prostate cancer, and it's for anyone interested in understanding what happens at the cellular level during this transformation, which could help find new treatments and ways to track the disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionEmory University
NIH-funded
Lab location1 site (Atlanta, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2029
Funding year2024
Award (this year)$541,236
NIH project number1R01CA286147-01A1
Project IDNIH-10982139 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with prostate adenocarcinoma who may be at risk of developing neuroendocrine prostate cancer.

Less likely to help

Patients with non-prostate cancers or those whose prostate cancer has already progressed to neuroendocrine type may not benefit from this research.

What this research studies

This research investigates the molecular changes that occur when prostate adenocarcinoma transforms into neuroendocrine prostate cancer, a more aggressive form of the disease. By studying specific genes and their effects on cell behavior over time, researchers aim to uncover the biological mechanisms driving this transformation. The approach involves manipulating prostate cancer cells in the lab to observe changes in gene expression and cellular structure, which may reveal potential targets for new treatments and biomarkers for disease progression.

Why it matters

Potential benefit: If successful, this research could lead to new treatment options and diagnostic tools for patients with neuroendocrine prostate cancer.

How similar studies have gone: While the specific approach of studying luminal-to-neuroendocrine transdifferentiation is novel, similar research has shown promise in understanding cancer progression and identifying treatment targets.

Where this research is happening

  • Emory University
    Atlanta, United States
    Active

Researchers

  • Principal investigator: Zhao, Changsheng — Emory University
  • Study coordinator: Zhao, Changsheng

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.